Funder: National Ataxia Foundation
Due Dates (Anticipated): August 2026 (Letter of Intent) | December 2026 (Full application)
Funding Amounts: Up to $100,000 for one year; direct research expenses only; no indirect costs allowed.
Summary: Supports research advancing therapies, biomarkers, and care for Spinocerebellar Ataxia Type 3 (SCA3), with a focus on bridging scientific discovery and clinical application.
Key Information: Forecasted cycle—dates are projected; check the program page for updates.